ONE-WAYOngoing theme · still written in the latest filings
Expansion of a Development Pipeline Centered on Fibrosis
A theme focused on expanding indications, conducting clinical trials and pursuing regulatory approval applications for fibrosis-related diseases, centered on F351 and AisuRui (pirfenidone), while expanding the development pipeline by adding multiple novel drug-discovery programs.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.
PeriodFY2016-Q3 →Still being written about.
Directionhelps1 helps · 0 hurts · 0 flat